<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635153</url>
  </required_header>
  <id_info>
    <org_study_id>DarDar 2-C CPHS 21592 D12221</org_study_id>
    <secondary_id>RO1 503498</secondary_id>
    <nct_id>NCT01635153</nct_id>
  </id_info>
  <brief_title>Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis</brief_title>
  <acronym>DarDar</acronym>
  <official_title>Randomized Controlled Trial of a Protein-calorie Supplement for HIV-infected Women With Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized, controlled trial is to determine if adding a&#xD;
      protein-calorie supplement (PCS) to the standard treatments for tuberculosis (TB) and HIV&#xD;
      will improve health outcomes. The investigators will enroll 180 HIV-positive women with newly&#xD;
      diagnosed active TB and without prior anti-retroviral therapy (ART). At baseline, the&#xD;
      investigators will conduct dietary interviews, measure body composition, randomize subjects&#xD;
      to receive a PCS (plus micronutritional supplements [MNS]) or control (MNS only) for the&#xD;
      6-month duration of anti-TB therapy (ATT) plus an additional 2 mos (8 mos total). Subjects&#xD;
      will be followed monthly and have CD4 counts at baseline, 2, 8 and 12 months. At 2 months&#xD;
      (i.e., at the end of the 4 drug intensive phase of TB treatment and start of the 2 drug&#xD;
      continuation phase), all subjects will be started on anti-retroviral therapy (ART) based on&#xD;
      Tanzanian Ministry of Health guidelines (currently: AZT/3TC/efavirenz). The primary endpoint&#xD;
      will be change in CD4 count after 8 months (i.e., at end of PCS/MNS intervention and 2 months&#xD;
      after completion of ATT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this randomized, controlled trial is to determine if adding a&#xD;
      protein-calorie supplement (PCS) to the standard treatments for tuberculosis (TB) and HIV&#xD;
      will improve health outcomes. The investigators will enroll 180 HIV-positive women with newly&#xD;
      diagnosed active TB and without prior anti-retroviral therapy (ART). At baseline, the&#xD;
      investigators will conduct dietary interviews, measure body composition, randomize subjects&#xD;
      to receive a PCS (plus micronutritional supplements [MNS]) or control (MNS only) for the&#xD;
      6-month duration of anti-TB therapy (ATT) plus an additional 2 mos (8 mos total). Subjects&#xD;
      will be followed monthly and have CD4 counts at baseline, 2, 8 and 12 months. At 2 months&#xD;
      (i.e., at the end of the 4 drug intensive phase of TB treatment and start of the 2 drug&#xD;
      continuation phase), all subjects will be started on anti-retroviral therapy (ART) based on&#xD;
      Tanzanian Ministry of Health guidelines (currently: AZT/3TC/efavirenz). The primary endpoint&#xD;
      will be change in CD4 count after 8 months (i.e., at end of PCS/MNS intervention and 2 months&#xD;
      after completion of ATT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Protein-calorie supplement plus micronutrient vs micronutrient alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD4 Count</measure>
    <time_frame>Baseline to 8 months</time_frame>
    <description>We will calculate change in CD4 count from start of ART until 6 mos on ART (which is started 2 mos after study enrollment, hence 8 mos after enrollment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI at 6 Months</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>BMI will be compared between the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Achieve 100 Cell Increase in CD4</measure>
    <time_frame>baseline to 8 months</time_frame>
    <description>Number of subjects in 2 treatment groups who achieve 100 cell increase in CD4 will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>HIV</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Protein calorie supplement plus micronutrient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronutrient alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein calorie supplement</intervention_name>
    <description>Fortified porridge with 1062 kcal and 40 gm protein</description>
    <arm_group_label>Protein calorie supplement plus micronutrient</arm_group_label>
    <other_name>Dar-uji</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Micronutrient</intervention_name>
    <description>Dar-vite Multivitamin</description>
    <arm_group_label>Micronutrient alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female,&#xD;
&#xD;
          -  HIV,&#xD;
&#xD;
          -  age &gt; 18,&#xD;
&#xD;
          -  CD4 &gt; 50,&#xD;
&#xD;
          -  BMI&gt;16&#xD;
&#xD;
          -  new TB diagnosis,&#xD;
&#xD;
          -  not on anti-retroviral therapy,&#xD;
&#xD;
          -  residence in Dar es Salaam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current anti-retroviral therapy,&#xD;
&#xD;
          -  serious co-morbidities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles F. von Reyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nyasule Majura-Neke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Muhimbili University of Health and Allied Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Disease Centre</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>C. Fordham von Reyn</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micronutrients</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Protein Calorie Supplement Plus Micronutrient</title>
          <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
        </group>
        <group group_id="P2">
          <title>Micronutrient Alone</title>
          <description>Micronutrient: Dar-vite Multivitamin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Non-malnourished women with newly diagnosed TB and newly diagnosed HIV, not on ART at time of enrollment</population>
      <group_list>
        <group group_id="B1">
          <title>Protein Calorie Supplement Plus Micronutrient</title>
          <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
        </group>
        <group group_id="B2">
          <title>Micronutrient Alone</title>
          <description>Micronutrient: Dar-vite Multivitamin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" lower_limit="33.5" upper_limit="44.5"/>
                    <measurement group_id="B2" value="36" lower_limit="31" upper_limit="43"/>
                    <measurement group_id="B3" value="37" lower_limit="32" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in CD4 Count</title>
        <description>We will calculate change in CD4 count from start of ART until 6 mos on ART (which is started 2 mos after study enrollment, hence 8 mos after enrollment)</description>
        <time_frame>Baseline to 8 months</time_frame>
        <population>Women with newly diagnosed TB and newly diagnosed HIV, not on ART</population>
        <group_list>
          <group group_id="O1">
            <title>Protein Calorie Supplement Plus Micronutrient</title>
            <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
          </group>
          <group group_id="O2">
            <title>Micronutrient Alone</title>
            <description>Micronutrient: Dar-vite Multivitamin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count</title>
          <description>We will calculate change in CD4 count from start of ART until 6 mos on ART (which is started 2 mos after study enrollment, hence 8 mos after enrollment)</description>
          <population>Women with newly diagnosed TB and newly diagnosed HIV, not on ART</population>
          <units>increase in CD4 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215" spread="28"/>
                    <measurement group_id="O2" value="174" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI at 6 Months</title>
        <description>BMI will be compared between the two treatment groups</description>
        <time_frame>baseline to 6 months</time_frame>
        <population>Women with newly diagnosed TB and newly diagnosed HIV not on ART</population>
        <group_list>
          <group group_id="O1">
            <title>Protein Calorie Supplement Plus Micronutrient</title>
            <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
          </group>
          <group group_id="O2">
            <title>Micronutrient Alone</title>
            <description>Micronutrient: Dar-vite Multivitamin</description>
          </group>
        </group_list>
        <measure>
          <title>BMI at 6 Months</title>
          <description>BMI will be compared between the two treatment groups</description>
          <population>Women with newly diagnosed TB and newly diagnosed HIV not on ART</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="5.73"/>
                    <measurement group_id="O2" value="24.7" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Achieve 100 Cell Increase in CD4</title>
        <description>Number of subjects in 2 treatment groups who achieve 100 cell increase in CD4 will be compared</description>
        <time_frame>baseline to 8 months</time_frame>
        <population>Women with newly diagnosed TB and newly diagnosed HIV not yet on ART</population>
        <group_list>
          <group group_id="O1">
            <title>Protein Calorie Supplement Plus Micronutrient</title>
            <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
          </group>
          <group group_id="O2">
            <title>Micronutrient Alone</title>
            <description>Micronutrient: Dar-vite Multivitamin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieve 100 Cell Increase in CD4</title>
          <description>Number of subjects in 2 treatment groups who achieve 100 cell increase in CD4 will be compared</description>
          <population>Women with newly diagnosed TB and newly diagnosed HIV not yet on ART</population>
          <units>N of subjects with CD4 increase of ≥100</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <desc>Standard definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Protein Calorie Supplement Plus Micronutrient</title>
          <description>Protein calorie supplement: Fortified porridge with 1062 kcal and 40 gm protein</description>
        </group>
        <group group_id="E2">
          <title>Micronutrient Alone</title>
          <description>Micronutrient: Dar-vite Multivitamin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Many patients were lost to follow-up which may interfere with the evaluation of treatment effects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr C Fordham von Reyn</name_or_title>
      <organization>Dartmouth-Hitchcock</organization>
      <phone>6036507167</phone>
      <email>fvr@dartmouth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

